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Abstract 
This study outlines the analysis of mitochondrial toxicity for a variety of pharmaceutical 
drugs extracted from Zhang et al. These chemicals were grouped into categories based upon 
structural similarity. Subsequently, mechanistic analysis was undertaken for each category to 
identify the Molecular Initiating Event driving mitochondrial toxicity. The mechanistic 
information elucidated during the analysis enabled mechanism-based structural alerts to be 
developed and combined together to form an in silico profiler. This profiler is envisaged to be 
used to develop chemical categories based upon similar mechanisms as part of the Adverse 
Outcome Pathway paradigm. Additionally, the profiler could be utilised in screening large 
dataset in order to identify chemicals with the potential to induce mitochondrial toxicity. 
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 Introduction 
Over the past decade a number of changes have occurred in European Union 
chemicals policy that have led to an increase in efforts to develop alternative methods to 
traditional animal testing for risk assessment.
1-7
 These alternatives have been developed 
employing in silico, in chemico and in vitro methods focussing on replacing or reducing 
animals used in short-term toxicity tests
8
. In order to be relevant, and useful, for regulatory 
assessment these alternatives should be based upon specific in vivo endpoints. Within recent 
years, interest has grown in developing a greater understanding of toxicity pathways. One 
such pathway approach is the Adverse Outcome Pathway (AOP) paradigm. An AOP is a 
framework that means to establish a mechanistic connection between an upstream Molecular 
Initiating Event (MIE) and a downstream adverse outcome relevant for risk assessment.
9-12
 
The MIE is the critical event in the progression of an AOP as it provides insight into the 
initial interaction(s) between the chemical behaviour of the xenobiotic and the biological 
system that initiates the perturbation of the normal pathway. Elucidation of the mechanistic 
information relating to specific MIEs enables the identification of structural (and physico-
chemical) features of chemicals that are responsible for the interaction with biological 
macromolecules, thus, facilitating the development of structural alerts. When utilised together, 
multiple structural alerts pertaining to the same MIE form the basis of an in silico profiler.
13-
16
 The information within an in silico profiler can, in turn, be used to develop chemical 
categories centred on a common MIE (note that multiple MIEs can be initiated by a single 
chemical). This allows for read-across and data gap filling to be applied. The premise behind 
these structurally developed categories is that similar chemicals should have similar 
biological activities and therefore, should have the same MIE. Furthermore, the categories 
produced using in silico profilers can be supported by, and used to prioritise, additional 
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testing using in vitro and/or in chemico methods, within an integrated testing strategy. Such 
strategies can be used for hazard identification and risk assessment purposes, as well as being 
incorporated into in silico software tools such as the OECD QSAR Toolbox.
10-11, 16-18
 
A number of in silico profilers have been developed for a variety of organ-level 
toxicities, such as skin sensitisation, respiratory sensitisation, genotoxicityand 
hepatotoxicity.
13-15, 19-21
 However, very few profilers have dealt with toxicity induced by 
mitochondrial dysfunction.
1,22,23
 This is, in part, due to the number of mechanisms by which a 
chemical could induce mitochondrial dysfunction
24
. An additional complication is that a 
single chemical might have the ability to induce more than one of these mechanisms, making 
it difficult to define a single MIE within the AOP paradigm.  Over the past decade, interest in 
screening chemicals for an ability to induce mitochondrial dysfunction has increased.
24,25
This 
is, in part, due to the withdrawal of a number of pharmaceuticals from the market after 
observed mitochondrial dysfunctions.
26-31
 Toxicity to mitochondria has led to such 
withdrawals as these are important organelles present within almost every cell type of the 
body, the exception being mature erythrocytes.
32,33
 The basic structure and function of 
mitochondria consists of two membranes, the outer and inner membrane, enclosing three 
compartments, the inter membrane space, the cristae and the mitochondrial matrix. The outer 
membrane is relatively smooth and permeable to molecules that are less than 5kDa in size. In 
contrast, the inner membrane contains multiple invaginations (cristae), is impermeable to all 
molecules except O2, CO2, and H2O and contains each of the protein complexes within the 
electron transport chain, ATP synthase (Complex V) and various electron carriers. The 
mitochondria are responsible for a number of tasks vital to a cell’s normal functioning and 
survival. These tasks include the production of approximately 95% of the total amount of 
Adenosine Tri-Phosphate (ATP) generated by cells during oxidative phosphorylation. 
Oxidative phosphorylation is a process whereby energy from the transfer of electrons, 
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generated by the oxidation of Nicotinamide Adenine Dinucleotide (NADH) and Flavin 
Adenine Dinucleotide (FADH2), along various complexes of the electron transport chain is 
used to pump protons across the inner mitochondrial membrane generating an 
electrochemical gradient. The electron transport chain comprises four complexes situated 
within the inner mitochondrial membrane. Complexes I and II are involved in the oxidation 
of NADH and FADH2 respectively, providing the input of electrons into the respiratory chain. 
Complexes I, III and IV use the energy released from the transfer of electrons along the 
electron transport chain to pump protons out of the mitochondrial matrix into the inter 
membrane space.
25,31,34
 Complex V, the terminal complex involved in oxidative 
phosphorylation, utilises the electrochemical gradient produced to transfer protons from the 
inter membrane space back into the mitochondrial matrix. The energy released from this 
action is used to phosphorylate adenosine diphosphate into ATP. 
Previous research has shown that mitochondrial dysfunction may be induced by a 
range of chemicals and has been linked to a variety of organ toxicities within kidney, liver 
and nervous tissues.
26-31,35
 The most susceptible tissues to mitochondrial dysfunction are 
those containing a higher concentration of mitochondria or those exposed to a higher 
concentration of chemical: such as the liver, kidneys and heart.
24,25,28,36
 Five general 
mechanisms of mitochondrial dysfunction have been identified,
36,37
 inhibitors of the electron 
transport chain and ATP synthase (Complex V), uncouplers of oxidative phosphorylation, 
opening of the membrane permeability transition pore, inhibition of fatty acid β-oxidation, 
and oxidation or inhibition of mitochondrial DNA.  
As an example of the importance of mitochondrial toxicity approximately 35%, of more than 
500 pharmaceutically relevant chemicals, have been shown to be directly involved in 
impairing normal mitochondrial functioning by inhibition of the electron transport chain 
and/or by uncoupling of oxidative phosphorylation.
38
 Additionally, there are chemicals that 
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can induce mitochondrial toxicity via alternative mechanisms, such as inducing the 
membrane permeability transition, inhibition of β-oxidation of mitochondrial fatty acids, or 
interfering with mitochondrial DNA. Briefly stated, chemicals that inhibit the electron 
transport chain can do so by either direct binding to the complexes of the electron transport 
chain or ATP synthase or by acting as an alternative electron acceptor.
27,36,37
 The inhibition of 
electron flow along the electron transport chain by both of these mechanisms induces the 
formation of reactive oxygen species resulting in oxidative stress.
27,36,37
 Uncouplers of 
oxidative phosphorylation induce mitochondrial toxicity by shuttling protons into the 
mitochondrial matrix, via the inner mitochondrial membrane, bypassing ATP synthase. This 
assisted transport of protons back into the matrix dissipates the electrochemical potential, 
resulting in the loss of ATP production and, ultimately, cell death.
27,31,36,37,39-43
 Induction of 
the membrane permeability transition increases the permeability of the inner mitochondrial 
membrane to low molecular weight solutes (<1500Da), leading to a disruption of the electron 
transport chain, loss of membrane potential, and swelling of both the inner- and outer 
mitochondrial membranes.
44,45
 Inhibition of β-oxidation of mitochondrial fatty acids reduces 
the amount of NADH and FADH2 available for oxidative phosphorylation that, in turn, 
reduces ATP production.
46
 Mitochondrial DNA encodes 13 components of the electron 
transport chain, damage that occurs to mitochondrial DNA can have a variety of downstream 
effects depending upon where it occurs.
36,46
 It should be noted, however, that there is the 
potential that multiple, competing, mechanisms could initiate mitochondrial toxicity observed 
for a single (group of) chemical(s), i.e. one chemical may induce several MIEs. 
Given the importance of mitochondria within most cell systems, and the wide range of 
organ-level toxicities that may arise from mitochondrial dysfunction, the aim of the study was 
to identify structural alerts that could be used to form an in silico profiler suitable for 
grouping chemicals into mechanism-based categories. 
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Methods 
Data set 
A set of 288 chemicals were extracted from Zhang et al.
1
 This article was chosen for 
use as it provides one of the largest freely available datasets, for which the chemical list has 
qualitative mitochondrial toxicity data associated with it. Within this data set 171 chemicals 
have been reported within the literature as inducing mitochondrial toxicity and were therefore 
considered to be mitochondrial toxicants. The chemicals with a negative result for 
mitochondrial toxicity were selected from the FDA-approved drug list, whereby the 
therapeutic action mechanism, of common and safe oral drugs, was not associated with a 
mechanism of drug-induced mitochondrial toxicity. Given the lack of supporting mechanistic 
information to confirm the presence, or absence, of mitochondrial toxicity additional analysis, 
was carried out as detailed below. The full dataset is available in the supplementary 
information. Positive and negative chemicals were taken as documented in Zhang et al (Table 
S1in supporting information). 
Category formation based upon structural similarity 
All chemical structures were encoded into Simplified Molecular-Input Line-Entry 
System (SMILES) strings, neutralised and had salts removed. Each of the SMILES strings 
was extracted from the Royal Society of Chemistry’s ChemSpider website.
47
 Similarity 
calculations were implemented within the freely available Toxmatch software (v1.07) using 
the atom environment nearest neighbour approach, generating a data matrix with a Tanimoto 
similarity score for each chemical to all others within the data set. Subsequently, in-house 
code was implemented within Microsoft Excel that identified analogues with a similarity 
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index of 0.6 or greater; this was used in order to develop categories for the chemicals within 
the dataset with two, or more, analogues. Further analysis was undertaken upon those 
categories that met the following criteria: they contained three or more chemicals and at least 
one mitochondrial toxic chemical.  
Mechanistic hypothesis and the development of alerts 
Once categories had been developed using structural similarity a detailed search of the 
available literature was undertaken to elucidate the mechanistic information behind the 
molecular initiating event, along with other downstream key events, leading to the disruption 
of the mitochondria. This mechanistic information was subsequently utilised to support the 
definition of a structural alert suitable for grouping chemicals. These structural alerts were 
defined by identifying the common fragment present within each of the chemicals found to 
have positive mitochondrial toxicity according to literature information associated with them. 
Any additional information regarding the limits of the fragment found during the literature 
search, such as the requirement for an electron withdrawing group or the type of bond needed 
(e.g. a tertiary amine), was used to further refine the structural alert. The resulting alerts were 
subsequently defined as SMARTS patterns.
48
 A structural alert was only developed if 
information linking category members to mitochondrial toxicity was present within the 
scientific literature. The benefit of undertaking the analysis for each category is that it 
enabled the chemical space associated with a known, and tested, mechanism of mitochondrial 
toxicity to be identified. The development of chemical categories and identification of 
additional mechanistic information from the literature was crucial in addressing the 
limitations of the information in the original dataset. All structural alerts are available in the 
supplementary information and a KNIME workflow containing the structural alerts can be 
found in the COSMOS space which is a freely available tool 
(http://cosmosspace.cosmostox.eu/app/login). 
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Results and discussion  
The aim of this study was to develop an in silico profiler for mitochondrial toxicity 
based around clearly defined mechanistic information. This was achieved by grouping 
chemicals based upon their structural similarity, followed by a literature search to elucidate 
mechanistic information for the chemicals in categories associated with toxicity to 
mitochondria. Overall, 35 of the 288 chemicals were identified as belonging to categories 
containing mitochondrial toxic chemicals: local anaesthetics, antianginal, and antiarrhythmic; 
thiazolidinediones; nonsteroidal anti-inflammatory drugs; anthracycline antibiotics; 
perfluorinated chemicals; bile acids; phenothiazines; and β-blockers. A summary of the 
categories developed within this study is shown in Table 1. In total, eight categories were 
formed: two separate molecular initiating events for the perfluorinated chemical category 
were identified, whilst no structural alert for the β-blocker category could be defined. 
Subsequent mechanistic analysis showed the chemical within the eight categories covered 
five mechanisms of mitochondrial toxicity: inhibition of the electron transport chain, 
alternative electron acceptance, initiation of the death receptor pathway, uncoupling of 
oxidative phosphorylation and induction of the membrane permeability transition.  
Table 1: Chemicals grouped into categories using structural similarity and their associated 
mitochondrial toxicity   
Category 1: Local anaesthetics, antianginal and antiarrhythmic 
The local anaesthetics category consisted of six analogues, four of which are 
anaesthetics, with ranolazine and tocainide being an antianginal and antiarrhythmic 
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respectively. All but one of the chemicals, tocainide, has been shown to exhibit toxicity 
towards mitochondria. The category is supported by a number of studies that have uggested 
that such chemicals affect mitochondrial metabolism by uncoupling oxidative 
phosphorylation.
31,39,49-51
 This uncoupling has been suggested to be mediated by both the 
protonophoric properties and the pKa of these chemicals. As the pKa is relatively similar to 
the intracellular pH, the level of protonated and deprotonated chemical is roughly at 
equilibrium. The presence of deprotonated chemical within the inner membrane space means 
that protons can be scavenged. Subsequently, the protonated chemical can combine with a 
hydrophobic anion to form a neutral ion-pair complex, which can then migrate across the 
inner mitochondrial membrane into the matrix, where the complex dissociates and the proton 
is released. Both the chemical and the hydrophobic anion then return to the inner membrane 
space, continuing the cycle. This assisted transport of protons back into the matrix dissipates 
the electrochemical potential, resulting in a loss of ATP production and ultimately cell 
death.
31,39,41,42,51-53
 It has been suggested that bupivacaine, and other highly lipophilic 
anaesthetics, can also act to uncouple oxidative phosphorylation via the mechanism outlined 
above without the need to complex with a lipophilic anion.
49
 The presence, and pKa, of the 
tertiary amine group is thought to be responsible for the ability of these chemicals to 
scavenge protons within the inner membrane space. Therefore, the lack of a tertiary amine 
group offers an explanation as to why no mitochondrial toxicity has been associated with 
tocainide. 
Category 2: anti-diabetic drugs 
This category consists of three thiazolidinediones: pioglitazone, rosiglitazone, 
troglitazone: each of which were identified as inducing mitochondrial toxicity. 
Thiazolidinediones are the major orally administered drugs used in the treatment of Type 2 
(non-insulin dependent) diabetes. These drugs are used to improve insulin sensitivity and 
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lower blood glucose levels within diabetic patients. Many of the thiazolidinediones have been 
suspected of initiating hepatotoxicity via mitochondrial dysfunction.
29
 For example, 
troglitazone was withdrawn from the world market in 2000 due to hepatotoxicity observed in 
a number of patients.
27,51
 Research into the thiazolidinediones suggests the chemicals within 
this category elicit their mitochondrial dysfunction by inhibiting the electron transport chain 
and uncoupling oxidative phosphorylation.
22,26,29,51
 These drugs have been shown to inhibit 
the activity of mitochondrial complexes, the main target being Complex I.
26,27,51,54
 These 
chemicals decrease the membrane potential across the inner mitochondrial membrane which 
causes mitochondrial swelling and in turn induces mitochondrial permeability transition.
54,55
 
Additionally, thiazolidinediones have been shown to uncouple oxidative phosphorylation in a 
manner similar to that described above for the chemicals within category one.
22,26
 It is 
thought that the properties that enable the thiazolidinediones to bind to the nuclear PPAR-
gamma receptor confers the ability to bind to Complex I.
26
 Additionally, the heterocyclic 
properties of the ring system are thought to enable the thiazolidinedione to cycle between a 
protonated and deprotonated form conferring the ability to transport protons across the inner 
mitochondrial membrane thereby uncoupling oxidative phosphorylation.
22
 
Category 3: Nonsteroidal anti-inflammatory drugs 
The third category comprises three chemicals: mefenamic acid, flufenamic acid, and 
tolfenamic acid: each of which has been identified as being able to induce mitochondrial 
toxicity. Each of these three chemicals are part of a group of nonsteroidal anti-inflammatory 
(NSAIDs). NSAIDs are some of the most widely used pharmaceutical drugs on the market 
that are used for their analgesic, antipyretic and anti-inflammatory properties to reduce and 
relieve symptoms for a variety of conditions. In order for the anti-inflammatory properties 
associated with NSAIDs to be present a carboxylic acid moiety is needed.
51
. The carboxylic 
acid moiety acts to inhibit cyclooxygenase activity, an enzyme responsible for the production 
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of mediators of the inflammatory response, thereby reducing the level of inflammatory 
signalling. Previous research substantiates the positive mitochondrial toxicity result for each 
chemical within this category. A variety of literature sources identify each of these chemicals 
as having the ability to uncouple oxidative phosphorylation via a similar mechanism as that 
described above for the lidocaine category.
56-60
 However, due to their lipophilicity, these 
chemicals do not necessarily need to be associated with a separate hydrophobic anion in order 
to translocate into the mitochondrial matrix. The carboxylic acid moiety, which is required 
for the anti-inflammatory properties of the NSAIDs, is believed to also be required to induce 
the uncoupling ability of this group of chemicals.
51
 
Category 4: Anthracycline antibiotics 
Anthracycline antibiotics are a group of hydroxylated tetracycline quinones with a 
duanosamine sugar sidechain attached. One of the category members, doxorubicin, is one of 
the most widely used antineoplastic drugs within the U.S.
61
 Structural similarity identified 
three similar chemicals. A number of studies have shown that the anthracycline antibiotics 
cause mitochondrial dysfunction by acting as alternative electron acceptors interfering with, 
and inhibiting, the electron transport chain, leading to oxidative stress. This occurs because 
under normal physiological conditions anthracyclines are usually deprotonated and can 
permeate across the outer mitochondrial membrane. Once within the inner mitochondrial 
space these chemicals disrupt the electron transport chain by sequestering an electron from 
Complex I and are thus reduced to a semiquinone radical intermediate.
61,62
 These 
semiquinone radicals subsequently interact with molecular oxygen present within the 
mitochondria, producing reactive oxygen species (ROS), including hydroxyl and superoxide 
anion radicals. Downstream these ROS lead to a variety of effects such a mitochondrial 
permeability transition induction and oxidative damage of DNA, proteins and lipids.
63-65
 Due 
to the high level of similarity between the chemicals it can be assumed that the mechanism of 
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action is conserved throughout the category. It should also be noted that quinones are also 
used as antimalarials which are known mitochondrial  toxicants.
66
 
 
Category 5: Hypolipodemic drugs  
Perfluorinated chemicals have been widely used in a variety of commercial and 
pharmaceutical products, such as flame retardants, surfactants and hypolipidemic drugs. 
These hypolipidemic drugs induce the proliferation of peroxisomes and thus increase β-
oxidation of fatty acids. Three perfluorinated chemical analogues; perfluorodecanoic acid, 
perfluorooctanoic acid, perfluorooctane sulphonamide; were identified as having a high level 
of similarity. Despite the high levels of similarity between the chemicals. This highlights the 
need to undertake mechanistic analysis of the categories as structural similarity on its own is 
not enough. As is shown with this category slight variations in structure have the potential to 
induce different mechanistic pathways. Accordingly, information in the literature suggests 
that for this category there are two potential mechanisms by which the perfluorinated 
chemicals elicit their mitochondrial toxicity; uncoupling of oxidative phosphorylation and 
induction of the mitochondrial membrane permeability transition pore. 
Perfluorooctane sulphonamide has been shown to uncouple oxidative phosphorylation 
in vitro via a protonophoric mechanism, similar to that described above, within various 
species
23,67-69
. In comparison to p-trifluromethoxyphenylhydrazone, one of the most potent 
uncouplers, perfluorooctane sulphonamide has been known to uncouple oxidative 
phosphorylation with a potency of a similar magnitude. It has been suggested that the pKa 
and ionisability of the amino acid moiety, in conjunction with the relatively high lipophilicity 
of the chemical, enables the shuttling of protons across the inner mitochondrial membrane 
into the matrix, dissipating the membrane potential.
69
 Starkov
 
studied the structural activity of 
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perfluoroalkanes and their ability to elicit mitochondrial toxicity via disruption to oxidative 
phosphorylation.
69
 Their data identified that a protonated nitrogen atom with a favourable 
pKa is essential to the uncoupling action of perfluorooctane sulphonamides in mitochondria. 
In addition, perfluorooctane sulphonamide is one of a very limited number of uncoupling 
chemicals that does not contain a ring structure
68
. In contrast, the perfluoroalkyl acids are 
believed to induce the mitochondrial membrane permeability transition at lower 
concentrations, whilst higher concentrations can uncouple oxidative phosphorylation
69-71
. It 
has been observed that perfluorodecanoic acid forms reactive oxygen species (ROS), 
hydrogen peroxide and peroxynitrite anion.
72
 The presence of elevated ROS levels initiates 
oxidative stress within mitochondria. Oxidative stress has been shown to induce the 
membrane permeability transition (MPT).
73,74
 The MPT is an increase in permeability of the 
inner mitochondrial membrane to low molecular weight solutes (<1500 Daltons). The 
subsequent influx of solutes into the matrix instigates swelling of the inner and outer 
membranes causing disruption of the electron transport chain and a release of apoptotic 
proteins such as cytochrome c.
23,72,75
 The uncoupling action of the two perfluoroalkyl acids is 
similar to that described for category one. Two alerts were defined due to two distinct MIEs 
being identified (Table 2). Previous research has shown there to be an increase in toxicity 
concomitant to an increase in alkyl side chain length up to C12, with the most marked increase 
in toxicity (a five- to ten- fold increase) occurring between C6 and C8 perfluoroalkyl acids 
and sulphates.
23
 An unsubstituted amide fragment has been shown to be required in order for 
uncoupling by perfluorinated sulphonamides to occur: fully substituted sulphonamides, which 
lack the protonated amide moiety, were found to lack the ability to uncouple oxidative 
phosphorylation.
69
 The carboxylic acid moiety of the perfluoroalkyl acids chemicals is 
thought to be responsible for the uncoupling action of these chemicals at higher 
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concentrations. However, it is unclear which fragments are required in the induction of the 
MPT. 
Category 6: Bile acids 
The bile acid category consists of twoprimary conjugate bile acids: glycocholic acid 
and taurocholic acid: and three non-conjugated secondary bile acids: deoxycholic acid, 
chenodeoxycholic acid and lithocholic acid: all with a high level of similarity to the primary 
bile acid; cholic acid. Bile acids are one of the main constituents of bile and are synthesised 
from cholesterol by hepatocytes and are then converted into secondary bile acids via the 
intestinal bacteria. They play a vital role in multiple functions within both the liver and 
intestines, the main function being the sequestration of fats within micelles for excretion. Bile 
acids have been shown to decrease the membrane potential of mitochondria, alongside a 
decrease in state 3 respiration and an increase in state 4 respiration. The specific cellular 
mechanism of bile acid-induced toxicity has not been elucidated. However, both the intrinsic 
(mitochondrial) and extrinsic (death receptor) pathways have been implicated in the 
disruption of normal mitochondrial function.  
Intrinsic pathway 
The intrinsic apoptotic pathway results in mitochondrial dysfunction due to an 
increase in intracellular stress. Hydrophobic bile acids have been shown to inhibit the 
electron transport chain by decreasing the activity of complexes I, III and IV, resulting in a 
decrease in state 3 respiration and a concomitant generation of ROS.
76-81
 It has been proposed 
that the inhibition of complex III leads to a subsequent electron leak through the ubiquinone-
complex III site and a concomitant ROS generation.
80,81
 The increased oxidant stress may 
then cause the induction of the MPT by oxidation of the thiol sites on the membrane 
permeability transition pore.
79
 Induction of the MPT triggers the release of cytochrome c, 
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thus, stimulating the translocation of Bax to the mitochondrial membrane, stimulating further 
release of cytochrome c.
82-84
 Cytochrome c is also able to initiate downstream caspase 
activation events discussed below.
77,78,81,84,85
 
Extrinsic pathway 
Mitochondrial dysfunction and apoptosis initiated via the extrinsic pathway results 
from extracellular signals triggering downstream caspase activity. The oxidative stress 
generated by bile acids induces an increased presentation of Fas receptor within the plasma 
membrane, following phosphorylation of the Fas receptor by the epidermal growth factor 
receptor.
78,86,87
 Upon presentation of Fas within the plasma membrane Fas agonists can 
interact with the receptor, initiating the formation of the death-inducing signalling complex 
(DISC) and subsequent activation of caspase-8. In turn, caspase-8 activates caspases-3 and -7 
triggering a caspase cascade that culminates in apoptosis.
78,84-86,88
 Additionally, caspase-8 can 
initiate the intrinsic pathway via proteolytic cleavage of Bid. Truncated Bid activates Bax and 
Bak proteins present on the mitochondria via oligomerisation and induction of MPT. The 
activated Bak and Bax proteins form channels within the mitochondria releasing additional 
cytochrome c. Cytosolic cytochrome c causes the assembly of apoptotic protease-activating 
factor-1 (APAF-1) and caspase-9, thus, activating caspase-9. Upon caspase-9 activation a 
proteolytic caspase cascade is initiated ultimately leading to cell death.
84,85
 The generation of 
ROS, induction of MPT and activation of the caspase cascade seem to be essential steps 
within both pathways to initiate mitochondrial perturbation and apoptosis. Therefore, it seems 
likely that both pathways work synergistically to induce mitochondrial dysfunction.  
Category 7: Antihistaminic, antipsychotic and antiemetic drugs  
Phenothiazines are a group of heterocyclic chemicals composed of a nitrogen and a 
sulphur atom joining two benzene rings. These chemicals are widely used in the treatment of 
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mental disorders, such as schizophrenia, psychosis, and anxiety, as well as conferring 
antihistaminic and antiemetic action. This category comprises seven chemicals: 
chlorpromazine, fluphenazine, mequitazine, methdilazine, promethazine, thiethylperazine, 
and trimeprazine: five of which have been identified have been identified as being non-toxic, 
whilst the remaining two have been shown to be toxic (Table 1). It is important to rationalise 
the mixed toxicity results for the chemicals within this category. A number of studies in the 
literature report toxicity induced by chlorpromazine and fluphenazinethat corroborate the data 
in the current study (obtained from Zhang et al).
 7,51,89-92
 
Both chlorpromazine and fluphenazine have been observed to inhibit mitochondrial 
respiration within brain and liver tissues 
93
 This toxicity was induced by binding to, and 
inhibiting, Complex I of the electron transport chain.
24,27,51
 Further investigation revealed that 
chlorpromazine is also capable of impairing mitochondrial function by inhibiting Complex 
IV and acting as an uncoupler of oxidative phosphorylation.
51,94,95
 It has been found that the 
addition of the chlorine atom increases and alters the mechanism by which mitochondrial 
toxicity occurs, i.e. chlorpromazine acts as an uncoupler of oxidative phosphorylation at low 
concentrations and an electron transport chain inhibitor at higher concentrations.
94
 Each 
chemical within this category contains a phenothiazine fragment. This class of drugs were 
found to cause toxicity towards mitochondria by inhibiting oxidative phosphorylation within 
liver mitochondria
96
. Due to this conserved fragment it can be hypothesised that the other 
chemicals within this category elicit their toxicity via a similar mechanism. Research into 
promethazine has shown that it can impede both state 3 and state 4 respiration and 
intramitochondrial potassium ion compartmentalisation at high and low concentrations.
94,95
 
Work carried out within Terada demonstrated that an acid dissociable group, bulky 
hydrophobic moiety and strong electron-withdrawing group are essential for the induction of 
uncoupling this conclusion can support why this class of drugs may act as uncouplers. 
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Further investigation into chlorpromazine reveals that this chemical elicits its electron 
transport chain inhibitor action by inhibiting Complex V of the electron transport chain. 
Based upon information in the literature both the tertiary amine moiety and the phenothiazine 
fragment with an associated electron-withdrawing group are required in order to initiate 
uncoupling of oxidative phosphorylation.
53
 
 
Category 8: β-blockers 
Alprenolol, propranolol and atenolol are a group of (non-)selective β-blockers used in 
the treatment of hypertension. As can be seen in Table 1 two chemicals, atenolol and 
propranolol, were reported within Zhang et al as inducing mitochondrial toxicity, whilst the 
remaining chemical, alprenolol, was reported as being negative for mitochondrial toxicity. 
Propranolol has been seen to inhibit, via non-competitive binding, Complex V of the 
respiratory chain. 
97,98
 Chemicals that inhibit Complex V can do so by binding to one of two 
subunits (FO/F1) that comprises the ATP synthase enzyme, thus blocking the passage of 
protons back into the mitochondrial matrix
98
. Together the membrane-bound F0 and matrix 
protruding F1 subunits are responsible for catalysing both the synthesis and hydrolysis of 
ATP. Wei et al
 
have described previously that propranolol binds to the Mg
2+
-ATPase (F0 
subunit) of Complex V inhibiting state 3 respiration.
98
 It has also been seen that the potency 
of ATPase inhibition induced by propranolol is of the same order of magnitude as its ability 
to inhibit other membrane-bound enzymes.
97
 Therefore, this inhibitory effect induced by 
propranolol is due to its membrane stabilising activity and its ability to bind to the lipophilic 
F0 subunit of Complex V. In contrast, atenolol, a relatively more hydrophilic drug, has been 
shown to act via stimulating Complex V activity. The decrease in lipophilicity and, therefore, 
a decrease in ability to penetrate and interact with membrane macromolecules is pertinent to 
the decrease in inhibitory potency of atenolol
97
. Additionally, results from Almotrefi suggest 
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that atenolol may interact with the more hydrophilic subunit (F1) of Complex V, resulting in 
mitochondrial toxicity by stimulating the hydrolysis of ATP to ADP and inorganic 
phosphate.
97
 Further research into how propranolol and atenolol is required in order to 
establish a clear structure-activity relationship for these structurally similar, β-blockers, given 
that they appear to have differing mechanisms of mitochondrial toxicity.  
 
Development of an in silico profiler for mitochondrial toxicity 
The ability to predict organ-level toxicity will become increasingly important to the 
long term goal of replacing animal use in determining a Lowest Observed (Adverse) Effect 
Level (LO(A)EL). Traditionally, LO(A)ELs are identified after undertaking a 28- or 90-day 
repeated dose study, with the lowest dose initiating a treatment related adverse effect in an 
organ(s) producing the LO(A)EL value. However, as no animal testing is permissible for 
cosmetic ingredients in Europe alternatives are required. As discussed previously this has led 
to increased interest in the understanding of toxicity pathways and in the development of 
AOPs. As such the structural alerts that have been developed in this study are intended for 
use in chemical risk assessment within the AOP paradigm. Within the AOP paradigm one of 
the roles of computational toxicology is to define the chemistry associated with key MIEs as 
an in silico profiler. To this end the mechanistic chemistry outlined in the current study was 
combined with that previously published by Naven et alenabling 17 structural alerts to be 
defined (Table 2).
22
 Briefly, Naven and co-workers analysed a database of more than 2000 
compounds resulting in the identification of eleven structural alerts associated with the 
uncoupling of oxidative phosphorylation (which was defined by an increase in basal 
respiration). The two sets of structural alerts are, in the most part, complimentary with only 
the thiazolinedione alert being identified in both studies. In addition, the majority of the 
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combined set of alerts identified relate to protonophoric mechanisms, with only two alerts for 
redox cycling (naphthoquinones and anthracene-9,10-diones) and only a single alert related to 
the inhibition of Complexes I-IV (phenothiazines). There is a clear need for additional 
structure-activity studies to define the chemical space for both these mechanisms, especially 
for chemicals capable of inhibiting Complexes I-IV. It should be noted that due to the 
limitations of the data available this study does not aim to create a profiler that would be used 
for pharmaceutical risk assessment, this study has highlighted the need for more 
mitochondrial chemical testing. 
Table 2: Summary of the structural alerts identified in the current study and from the work of 
Naven et al. For the structural alerts acting as protonophores the acidic hydrogen is as 
explicitly drawn. 
22
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AOP development 
Recently the development of AOPs has become an integral part of 21
st
 century 
toxicology, with the availability of the OECD AOP knowledgebase making AOP 
development a worldwide focus.
99
 In order for mitochondria-mediated AOPs to be developed, 
further investigation into the organ(s) affected is required; this was, however, beyond the 
scope of the current study. The main outcome from the current study is that the structural 
alerts defined enable chemicals to be grouped into mechanistically-based categories based 
around the knowledge of a number of key MIEs for mitochondrial toxicity. The resulting 
categories can thus be used for either prioritisation of chemicals for further in vitro testing or, 
where sufficient in vivo data exist, for read-across predictions of organ-level toxicity (from, 
for example, repeat dose toxicity testing). In terms of predicting organ-level toxicity in the 
future it is likely that additional steps in the AOP will need to be investigated within in vitro 
assays using a range of organ specific cell lines. For example, the use of primary human renal 
proximal tubule epithelial cells in the MTT assays to investigate nephrotoxicity due to 
mitochondrial dysfunction. This will enable a mechanistically-based weight of evidence to be 
constructed based around the AOP and allow the formation of AOPs based on mitochondrial 
dysfunction. Currently, chemistry-based grouping methods such as those outlined above offer 
the most immediate solution to risk assessment without using animals. 
Conclusions 
The aim of this study was to develop an in silico profiler for mitochondrial toxicity 
based around clearly defined mechanistic information utilising structural similarity and 
chemical category formation. The analysis resulted in the development of eight chemical 
categories and the definition of eight structural alerts. Importantly, these structural alerts were 
derived using mechanistic information in the available literature to elucidate knowledge of a 
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number of key Molecular Initiating Events that disrupt the normal functioning of 
mitochondria. The structural alerts developed within this study have been combined with 
those from the literature to create a single profiler useful for grouping chemicals into 
categories, thus, enabling predictions to be made regarding mitochondrial toxicity. It is 
envisaged that this profiler will help in the formation of a mitochondrial dysfunction AOP. 
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Tables 
Table 1 
Category Name Mitochondrial toxicity 
1 
(Local anaesthetics, antianginal and 
antiarrhythmic) 
Lidocaine Positive 
Bupivacaine Positive 
Etidocaine Positive 
Ropivacaine Positive 
Ranolazine Positive 
Tocainide Negative 
2 
(anti-diabetic drugs) 
Rosiglitazone Positive 
Pioglitazone Positive 
Troglitazone Positive 
3 
(Nonsteroidal anti-inflammatory drugs) 
Mefenamic acid Positive 
Flufenamic acid Positive 
Tolfenamic acid Positive 
4 
(Anthracycline antibiotics) 
 
Daunorubicin Positive 
Doxorubicin Positive 
Epirubicin Positive 
Idarubicin Positive 
5 
(Hypolipodemic drugs) 
Perfluorodecanoic acid Positive 
Perfluorooctanoic acid Positive 
Perfluorooctane-
sulphonamide 
Positive 
6 
(Bile acids) 
Cholic acid Positive 
Chenodeoxycholic acid Positive 
Deoxycholic acid Positive 
Glycocholic acid Positive 
Lithocholic acid Positive 
Taurocholic acid Positive 
7 
(Antihistaminic, antipsychotic and 
antiemetic drugs) 
Promethazine Negative 
Chlorpromazine Positive 
Fluphenazine Positive 
Mequitazine Negative 
Methdilazine Negative 
Thiethylperazine Negative 
Trimeprazine Negative 
8 
(β-blockers) 
Alprenolol Negative 
Atenolol Positive 
Propranolol Positive 
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Table 2 
Structural alert Source Mechanism Structural Alert 
Category 
(Table 1) 
2-(Dialkylamino)-N-(2,6-
dimethylphenylacetamides 
Current study Protonophore 
 
R = alkyl carbon 
1 
Thiazolidinediones 
Current study 
22
 
Protonophore 
 
2 
2-Anilinobenzoic acids Current study Protonophore 
O
H
O
N
H
 
3 
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Salicylates 
22
 Protonophore 
 
expands 3 
Anthranilic acids 
22
 Protonophore 
 
expands 3 
Anthracene-9,10-diones Current study 
Redox 
cycling 
 
4 
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Naphthoquinones 
22
 
Redox 
cycling 
 
expands 4 
Perfluorinated-carboxcylic-
acids 
Current study Protonophore 
 
n = 5-11 
5a 
Perfluorinated-sulphonamides Current study Protonophore 
 
n = 5-11 
5b 
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Bile acids Current study Unclear 
 
R = alkyl carbon 
6 
Phenothiazines Current study 
Inhibition of 
Complexes I-
IV 
 
R1 = CH2, CH3 
R2 = Cl, CF3 
7 
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Fluoromethylsulphanilides 
22
 Protonophore 
 
 
Nitrophenols 
22
 Protonophore 
 
 
Nitrosulphonanilides 
22
 Protonophore 
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Phenylhydrazones 
22
 Protonophore 
 
R = any carbon 
 
Thiadiazinedione dioxides 
22
 Protonophore 
 
R = any carbon 
 
Acylindolones 
22
 Protonophore 
 
R = alkyl carbon 
 
Page 38 of 39
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
39 
 
 
 
 
 
Page 39 of 39
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
